You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Harvard Business School
Moodys
Express Scripts
McKesson

Last Updated: August 11, 2020

DrugPatentWatch Database Preview

LOXAPINE SUCCINATE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Loxapine Succinate patents expire, and when can generic versions of Loxapine Succinate launch?

Loxapine Succinate is a drug marketed by Elite Labs Inc, Lannett Co Inc, Mylan, and Watson Labs. and is included in seven NDAs.

The generic ingredient in LOXAPINE SUCCINATE is loxapine succinate. There are eight drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the loxapine succinate profile page.

US ANDA Litigation and Generic Entry Outlook for Loxapine Succinate

A generic version of LOXAPINE SUCCINATE was approved as loxapine succinate by WATSON LABS on June 15th, 1988.

  Start Trial

Drug patent expirations by year for LOXAPINE SUCCINATE
Drug Prices for LOXAPINE SUCCINATE

See drug prices for LOXAPINE SUCCINATE

Recent Clinical Trials for LOXAPINE SUCCINATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Mylan PharmaceuticalsPhase 1

See all LOXAPINE SUCCINATE clinical trials

US Patents and Regulatory Information for LOXAPINE SUCCINATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Elite Labs Inc LOXAPINE SUCCINATE loxapine succinate CAPSULE;ORAL 076868-001 Aug 4, 2005 AB RX No No   Start Trial   Start Trial   Start Trial
Lannett Co Inc LOXAPINE SUCCINATE loxapine succinate CAPSULE;ORAL 090695-003 Sep 26, 2011 AB RX No No   Start Trial   Start Trial   Start Trial
Elite Labs Inc LOXAPINE SUCCINATE loxapine succinate CAPSULE;ORAL 076868-004 Aug 4, 2005 AB RX No No   Start Trial   Start Trial   Start Trial
Mylan LOXAPINE SUCCINATE loxapine succinate CAPSULE;ORAL 076762-004 Nov 1, 2004 AB RX No No   Start Trial   Start Trial   Start Trial
Lannett Co Inc LOXAPINE SUCCINATE loxapine succinate CAPSULE;ORAL 090695-004 Sep 26, 2011 AB RX No No   Start Trial   Start Trial   Start Trial
Watson Labs LOXAPINE SUCCINATE loxapine succinate CAPSULE;ORAL 072062-001 Jun 15, 1988 AB RX No No   Start Trial   Start Trial   Start Trial
Watson Labs LOXAPINE SUCCINATE loxapine succinate CAPSULE;ORAL 072205-001 Jun 15, 1988 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Harvard Business School
Johnson and Johnson
Baxter
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.